Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy InflaRx N-V stock

Learn how to easily invest in InflaRx N-V stock.

InflaRx N-V is a biotechnology business based in the US. InflaRx N-V shares (IFRX) are listed on the NASDAQ and all prices are listed in US Dollars. InflaRx N-V employs 44 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy InflaRx N-V stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – IFRX. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 in stock when you fund a new account within 30 days

Promoted for all-in-one investing

M1 Finance

  • Commission-free stock and ETF trades
  • No management fees
  • Customizable portfolios with automatic rebalancing

InflaRx N-V stock price (NASDAQ: IFRX)

Use our graph to track the performance of IFRX stocks over time.

InflaRx N-V shares at a glance

Information last updated 2023-06-04.
Latest market close$4.21
52-week range$0.78 - $7.25
50-day moving average $4.14
200-day moving average $2.83
Wall St. target price$9.63
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.65

Buy InflaRx N-V stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
Stocks, Options, ETFs, Cryptocurrency, Futures
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000 in stock
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
M1 Finance
Stocks, ETFs
Get $75 - $500
when you sign up and deposit min. $10,000 within 14 days. Terms and conditions apply
Build a custom portfolio of stocks and ETFs with automatic rebalancing.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency, Alternatives, Treasury Bills
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Earn a 5.4% yield with government-backed Treasury bills.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
Get $50 - $700
when you open and fund an account with $5,000 - $250,000+
Pay no commissions on stocks, ETFs, mutual funds and options.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy InflaRx N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

InflaRx N-V price performance over time

Historical closes compared with the close of $4.21 from 2023-06-02

1 week (2023-05-26) 1.20%
1 month (2023-05-05) -3.88%
3 months (2023-03-03) 131.32%
6 months (2022-12-05) 68.40%
1 year (2022-06-03) 186.39%
2 years (2021-06-04) 34.50%
3 years (2020-06-05) 7.49
5 years (2018-06-05) 37.33

InflaRx N-V financials

Gross profit TTM $0
Return on assets TTM -28.75%
Return on equity TTM -30.45%
Profit margin 0%
Book value $1.98
Market capitalisation $247.9 million

TTM: trailing 12 months

InflaRx N-V share dividends

We're not expecting InflaRx N-V to pay a dividend over the next 12 months.

InflaRx N-V share price volatility

Over the last 12 months, InflaRx N-V's shares have ranged in value from as little as $0.776 up to $7.25. A popular way to gauge a stock's volatility is its "beta".

IFRX.US volatility(beta: 0.97)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InflaRx N-V's is 0.9697. This would suggest that InflaRx N-V's shares are less volatile than average (for this exchange).

InflaRx N-V overview

InflaRx N. V. , a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co.

Frequently asked questions

What percentage of InflaRx N-V is owned by insiders or institutions?
Currently 13.099% of InflaRx N-V shares are held by insiders and 19.324% by institutions.
How many people work for InflaRx N-V?
Latest data suggests 44 work at InflaRx N-V.
When does the fiscal year end for InflaRx N-V?
InflaRx N-V's fiscal year ends in December.
Where is InflaRx N-V based?
InflaRx N-V's address is: Winzerlaer Str. 2, Jena, Germany, 07745
What is InflaRx N-V's ISIN number?
InflaRx N-V's international securities identification number is: NL0012661870
What is InflaRx N-V's CUSIP number?
InflaRx N-V's Committee on Uniform Securities Identification Procedures number is: N44821101

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site